Faculty & Staff

· Edwin Cheng
· Melanie Stapleton
· Michael Ma
· Nauzer Forbes
· Rachid Mohamed
· Robert Hilsden
· Shane Devlin
· Steven J. Heitman
· Syd Bass
· Sylvain Coderre
· Tarun Misra

Peter Lougheed Centre

Shane Devlin, MD, FRCPC

Clinical Assistant Professor of Medicine
Site Chief PLC, Inflammatory Bowel Disease Group

Phone: 403-277-7321  Fax: 403-277-7327

Curriculum Vitae

2005-2006 Advanced Fellowship in Inflammatory Bowel Disease Cedars-Sinai Medical Centre, Los Angeles California 2002-2004 Fellowship in Gastroenterology, University of Calgary 1999-2000 Residency in Internal Medicine, University of Calgary 1995-1999 Doctor of Medicine, University of Manitoba 1991-1995 Bachelors of Science, Zoology


Clinical/Research Interests

Dr. Devlin specializes in Inflammatory Bowel Disease research and is an active member of the clinical trial unit



Patient-specific approach to combination versus monotherapy with the use of antitumor necrosis factor α agents for inflammatory bowel disease Devlin SM, Cheifetz AS, Siegel CA; BRIDGe group. Gastroenterol Clin North Am. 2012 Jun;41(2):411-28.

Assessment of variables associated with smoking cessation in Crohn's disease. Leung Y, Kaplan GG, Rioux KP, Hubbard J, Kamhawi S, Stasiak L, Cohen RD, Devlin SM, Panaccione R, Hanauer SB, Rubin DT. Dig Dis Sci. 2012 Apr;57(4):1026-32.

Optimizing the safety of biologic therapy for IBD. de Silva S, Devlin S, Panaccione R.Nat Rev Gastroenterol Hepatol. 2010 Feb;7(2):93-101.

The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all. Melmed GY, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Siegel CA. Clin Gastroenterol Hepatol 2010;8(8):655-9.

Referring Physicians